KPTI - Karyopharm updates data for eltanexor in blood cancer study

Photo by ExperienceInteriors/E+ via Getty Images Karyopharm Therapeutics ([[KPTI]] +3.9%) announced the updated results from a Phase I/II study for eltanexor against hypomethylating agent ((HMA)) refractory myelodysplastic syndrome ((MDS)). The presentation at the 2021 American Society of Clinical Oncology ((ASCO)) Annual Meeting included data from 20 patients who received two daily doses of 10 mg (n=5) or 20 mg (n=10). 15 were evaluable of efficacy, the company said. Seven (47%) had marrow complete response ((mCR)), five (33%) had stable disease ((SD)) suggesting a total disease control rate (DCR, mCR+SD) of 80% (60% for all patients). In the 10mg cohort (n=5), all derived clinical benefit, Karyopharm said indicating that three patients (60%) reached mCR and two patients (40%) reached SD. Karyopharm has an agreement with Antengene to commercialize four drug candidates including eltanexor in certain markets in the Asia Pacific.  Antengene recently received the regulatory nod in China for an Investigational New

For further details see:

Karyopharm updates data for eltanexor in blood cancer study